Frabin Biomarker Diagnosis for Aggressive Epithelial Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and managing aggressive epithelial tumors, such as prostate cancer, are inadequate for early detection and prognosis, particularly in cases of androgen independence, leading to ineffective treatments.
Innovation Solution
The method involves assaying biopsy samples for FGD1-related F-actin binding protein (Frabin/FGD4) expression and miR-17-92 levels to differentiate between normal, benign, and aggressive tumors, allowing for targeted treatments like hormonal therapy or chemotherapy based on Frabin and miR-17-92 levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If prolonged androgen blockade therapy is administered, then initial treatment effectiveness is achieved, but resistance develops leading to castration resistant prostate cancer
Solution Approach 1:
The patent applies preliminary action by detecting Frabin expression levels in biopsy samples before and during hormone therapy to predict future resistance development. This allows clinicians to anticipate treatment failure and switch therapies before the cancer becomes fully resistant, thereby extending the effective duration of treatment.
Solution Approach 2:
The patent implements feedback by using Frabin expression analysis as a biomarker to monitor treatment response and predict resistance. The detection results provide feedback that guides treatment decisions, allowing dynamic adjustment of therapy based on the tumor's evolving characteristics rather than following a fixed treatment protocol.
2Measurement precision
If standard diagnostic methods are used, then general tumor detection is achieved, but early detection of aggressive androgen independent tumors is missed
Solution Approach 1:
The patent extracts and focuses on a specific biomarker (Frabin/FGD4) that is selectively expressed in aggressive, androgen-independent prostate tumors. By isolating this particular molecular indicator rather than using general diagnostic methods, the patent enables early and accurate detection of the most dangerous tumor types before they become clinically apparent.
Solution Approach 2:
The patent changes the diagnostic parameter from general histological examination to specific molecular expression analysis of Frabin. This parameter change allows differentiation between benign, androgen-sensitive, and androgen-independent tumors, providing earlier and more accurate diagnosis of aggressive cancers that would otherwise be missed by standard methods.
3Measurement precision
If Frabin expression is detected in luminal cells, then accurate tumor classification is achieved, but treatment complexity increases
Solution Approach 1:
The patent segments prostate tumors into distinct categories based on Frabin expression patterns: benign tumors (no Frabin), androgen-sensitive tumors (low Frabin), and androgen-independent aggressive tumors (high Frabin). This segmentation simplifies treatment decision-making by matching each category with appropriate therapy protocols rather than using a one-size-fits-approach.
Solution Approach 2:
The patent applies local quality by tailoring treatment protocols to the specific Frabin expression profile of each patient's tumor. Rather than applying uniform complex treatment regimens to all patients, the therapy is customized based on the local molecular characteristics of the tumor, simplifying the overall treatment approach for each individual case.
Data Source
AI summary
A biomarker is disclosed that can distinguish aggressive epithelial tumors in a tissue biopsy from, for example, normal, hyperplastic, and benign neoplastic tumors. The biomarker can also identify epithelial tumors that have become resistant to hormone therapy. Therefore, methods are disclosed for providing diagnosis and prognosis of a subject having, or suspected of having, an epithelial tumor, such as a prostate tumor.